Herantis Pharma Plc is a clinical-stage biotechnology company developing disease modifying therapies for Parkinson’s disease. Herantis’s lead product, HER-096 is a first-in-class agent in development for the treatment of Parkinson’s disease with disease modifying potential and convenient subcutaneous administration. Primary objective of the ongoing Phase 1b clinical trial is to assess the safety, tolerability and pharmacokinetics of repeated subcutaneous doses of HER-096; the trial will also evaluate selected biomarkers and monitor symptoms associated with Parkinson’s disease. Topline data from Phase 1b trial is expected in September 2025. The Phase 1b trial is funded by the Michael J. Fox Foundation for Parkinson’s Research (MJFF) and The Parkinson’s Virtual Biotech. Herantis is listed on the Nasdaq First North Growth Market Finland.
Company Details
- Employees
- 24
- Founded
- -
- Address
- Bertel Jungin Aukio 1, Espoo,southern Finland 02600,finland
- Phone
- +358 9 222 1195
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- herantis.com
- HQ
- Espoo, Southern Finland
Herantis Pharma Plc. Questions
Herantis Pharma Plc.'s helpline number is +358 9 222 1195
Herantis Pharma Plc.'s website is herantis.com
Herantis Pharma Plc.'s LinkedIn profile is https://fi.linkedin.com/company/herantis-pharma-plc
Herantis Pharma Plc. has
24 employees.
View email and phone details for 24
employees at Herantis Pharma Plc..
Herantis Pharma Plc.'s industry is
Biotechnology Research
Herantis Pharma Plc.'s top competitors are
Tilt Biotherapeutics Ltd,
Medfiles,
Faron,
Medix Biochemica,
Finvector Oy,
Oriola Corporation,
Orion Pharma,
Aidian,
Valo Therapeutics Ltd,
Nanoform.
Herantis Pharma Plc.'s categories are Biotechnology Research
Herantis Pharma Plc.'s founding year is 2008
